Skip to main content
Menu

Respiratory - Monthly Reports

List of monthly reports on Respiratory

Respiratory Research Analysis

February’s respiratory research coalesced around five practice-informing directions: scalable digital stewardship that sharply reduces antibiotics for ARIs; host-directed immunometabolism (PHGDH/serine) that mitigates hyperinflammation and mortality in bacterial pneumonia models; clade‑resolved pneumococcal vaccine effects on nasopharyngeal colonization that directly inform adult policy; a lung–heart axis in influenza implicating cardiomyocyte IFNAR1 in cardiac injury; and a phase 3 trial showin

Respiratory Research Analysis

January’s respiratory research emphasized translationally actionable biology with sustained signals across COPD, post-viral lung disease, and respiratory infection prevention. Multi-omics Mendelian randomization and in vivo validation positioned SERPING1 (complement regulation) as a causal COPD modulator, while a large single-nucleus/spatial COPD atlas linked tissue cell states to accessible plasma biomarkers. A multicountry phase 2b trial showed oral nalbuphine ER meaningfully reduces objective

Respiratory Research Analysis

December’s respiratory research coalesced around five themes: host-directed antivirals, immune endotype switching in airway disease, epithelial–immune crosstalk in lung repair, multimodal AI diagnostics, and pediatric structural virology. A conserved HGS–coronavirus M interface emerged as a druggable host target with in vivo activity, while IL-17C–IL-17RE signaling was identified as a driver of neutrophilic endotype switching in bronchiectasis–asthma overlap. Dysplastic epithelial repair program

Respiratory Research Analysis

November’s respiratory research converged on prevention, host-directed therapeutics, and rapid biologics design. Top studies revealed a maternal immunity–neonatal RSV interaction that programs early-life asthma risk, and identified a modifiable vascular pathway (P-selectin) that mediates coronavirus–platelet/endothelium interactions with in vivo clearability. Scalable public-health nudges substantially increased influenza vaccine uptake, while a protein language model enabled de novo paired-chai

Respiratory Research Analysis

October’s respiratory research converged on three sustained directions: mechanism-guided repair of alveolar injury, pharmacologic therapy for obstructive sleep apnoea (OSA), and pandemic vaccine platform readiness. mTOR–IL-6–Edn1–FoxO1 signaling was linked to AT2 senescence in LAM with reversal using approved agents, charting a repurposing path. A multicentre phase 2 RCT showed clinically meaningful, dose-dependent benefits of sultiame for OSA, opening a new therapeutic class beyond devices. Rep

Respiratory Research Analysis

September’s respiratory literature emphasized prevention and mechanistic insights with immediate clinical relevance. A nationwide registry-linked randomized trial demonstrated that an RSV prefusion F vaccine substantially reduced RSV-related hospitalizations in adults ≥60. In parallel, a translational study in AERD connected alcohol-triggered symptoms to type-2 cytokine suppression of epithelial ALDH2 and showed therapeutic reversibility with dupilumab. Pediatric prevention advanced with a live-

Respiratory Research Analysis

August’s respiratory research delivered practice-shaping evidence and translational advances. A phase 3 NEJM trial showed inhaled molgramostim improves gas exchange and quality of life in autoimmune pulmonary alveolar proteinosis, while a large BMJ RCT found lateral positioning during procedural sedation significantly lowers hypoxaemia and airway rescues. Convergent biomarker and genetic evidence prioritized IL‑6 inhibition for pleural infection, and an interpretable AI achieved scalable, oximet

Respiratory Research Analysis

July’s respiratory research emphasized translation from mechanisms to practice. Structural virology clarified ACE2 usage by HKU5 merbecoviruses, refining spillover risk assessment and priorities for pan‑merbecovirus vaccine design. An externally validated, open‑source EHR/NLP pipeline markedly improved automated recognition of ARDS, enabling standardized care and trial enrollment. Population analyses defined a prognostically important young‑onset COPD phenotype, while single‑cell studies in post

Respiratory Research Analysis

June’s respiratory research delivered practice-shifting advances across oncology, tuberculosis, vaccines, and AI-driven discovery. Two large phase 3 trials reshaped thoracic oncology: a DLL3-directed T‑cell engager (tarlatamab) improved survival in relapsed SCLC, and a third‑generation EGFR TKI (limertinib) more than doubled PFS versus gefitinib. A four‑month clofazimine‑containing regimen supported safe treatment shortening for drug‑susceptible pulmonary TB, while an affordable, locally manufac

Respiratory Research Analysis

May’s respiratory research emphasized prevention, early detection, and practice-changing therapeutics. After score normalization with recency weighting, the top signals were an anti-inflammatory reliever strategy in mild asthma (as-needed albuterol–budesonide), a blood TCR signature enabling preclinical detection of nasopharyngeal carcinoma, clonal field biology redefining early squamous lung carcinogenesis, a PDE4B inhibitor (nerandomilast) slowing FVC decline in IPF, and intramuscular naloxone

Respiratory Research Analysis

March 2025 respiratory research converged on host–pathogen interfaces, tissue-resident immunity, and evolution-resilient biologics. A Nature study identified MFSD6 as the cellular entry receptor for EV‑D68, immediately enabling receptor‑blocking and decoy strategies. Immunity revealed lung‑resident memory B cells as the engine of persistent airway IgE, reframing durable control strategies for allergic disease. Methodologically, AI/structure‑guided redesign restored broad SARS‑CoV‑2 neutralizatio

Respiratory Research Analysis

January’s respiratory research spotlighted foundational shifts in airway biology and host–pathogen dynamics. A conserved perinatal innate‑immune defect in cystic fibrosis and an oxygen–metabolism axis controlling airway epithelial fate reframed early disease mechanisms and regeneration. RNA‑level evolution in SARS‑CoV‑2 (TRS/sgRNA innovations) emerged as a key driver of interferon evasion, complementing advances in large‑animal translational models (human ACE2 pigs) that accelerate countermeasur